Current Class Of Risk Evaluation & Mitigation Strategies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Here is a general outline of the REMS FDA has mandated so far, as well as a listing of drugs where it has been announced that REMS are being developed or drugs with safety issues that could invoke a REMS.
You may also be interested in...
Reckitt Targets UK's Painful ‘Tweens’ With Double-Strength Nurofen
Reckitt Benckiser wants to give British parents more pain relief options for their teens and "tweens."
Novartis’s New Eye Treatment Beovu Gets CHMP Nod
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
Xellia and Kabi Broaden US Antibiotics Offering
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports